An RNAi Therapy That Attenuates Multi-Organ Viremia and Improves Animal Survival in a Lethal EMCV Challenge Model.

Yaxin Zhang, Jiayu Yue, Bei Wu, Jingying Xie, Jiying Xu, Wenqing Gao, Ruofei Feng, Adi Idris

Abstract read

In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yaxin ZhangEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China.

Jiayu YueKey Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China.

Bei WuEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China.

Jingying XieEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China.ORCID 0009-0003-4268-8069

Jiying XuSchool of Life Sciences and Engineering, Northwest Minzu University, Lanzhou 730030, China.

Wenqing GaoCentre for Immunology and Infection Control, School of Biomedical Sciences, Queensland University of Technology, Kelvin Grove, QLD 4702, Australia.

Ruofei FengEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China.ORCID 0000-0001-9647-2827

Adi IdrisCentre for Immunology and Infection Control, School of Biomedical Sciences, Queensland University of Technology, Kelvin Grove, QLD 4702, Australia.ORCID 0000-0002-0562-1549

Funding

Fundamental Research Funds for the Central Universities 31920240125-01National Health and Medical Research Council APP2027569National Natural Science Foundation of China 32260037Open Funds of the Biomedical Research Center from Northwest Minzu University BRC-KF202402

6 · The paper itself

Abstract

Encephalomyocarditis virus (EMCV) is an important zoonotic pathogen that infects many animals with mild symptoms. However, swine is the most receptive host and causes acute and lethal myocarditis and/or encephalitis, and induces sudden death in piglets. There are currently no approved antivirals against EMCV. In recent years, antiviral therapies based on small interfering RNA (siRNA) have been rapidly developed as effective alternative therapies. In this study, we designed siRNAs targeting highly conserved regions in the EMCV genome coinciding with VP2 and 3C genes. We show that these siRNAs were non-immunostimulatory and significantly inhibited EMCV replication in vitro. The siRNAs were then complexed in liposomes before testing in a lethal EMCV mouse model in vivo. Both prophylactic and therapeutic intravenous delivery of siRNAs ameliorated viral infection in multiple organs and improved animal survival. This is the first demonstration of the use of a liposomal delivery platform to deliver highly conserved anti-EMCV siRNAs for EMCV antiviral therapy in vivo.

Indexed as

Cardiovirus InfectionsEncephalomyocarditis virusRNAi TherapeuticsRNA, Small InterferingViremiaAnimalsAntiviral AgentsDisease Models, AnimalLiposomesMiceRNA InterferenceSwineVirus ReplicationAntiviral AgentsLiposomesRNA, Small InterferingEMCVnanoparticlesRNAisiRNA

Identifiers

PMID41012668

DOI10.3390/v17091240

PMCPMC12474460

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.